Banjac Igor, Petrovic Marija, Akay Mehmet H, Janowiak Lisa M, Radovancevic Rajko, Nathan Sriram, Patel Manish, Loyalka Pranav, Kar Biswajit, Gregoric Igor D
From the Center for Advanced Heart Failure, University of Texas Health Science Center at Houston/Memorial Hermann Hospital - Texas Medical Center, Houston, Texas.
ASAIO J. 2016 Jan-Feb;62(1):e1-4. doi: 10.1097/MAT.0000000000000275.
Cardiovascular complications during or after transcatheter aortic valve replacement (TAVR) are associated with extremely high mortality, but extracorporeal membrane oxygenation (ECMO) can be used as procedural rescue option to improve outcomes when patients experience respiratory or cardiac arrest. From 2012 to 2014, 230 patients underwent TAVR and 10 patients (4.3%) required emergent venous-arterial ECMO support. Mean age was 83 years, median Society of Thoracic Surgeons (STS) score was 15, and mean aortic gradient was 45 mm Hg. Median left ventricular ejection fraction was 35%. Access for most ECMOs was femoral; two patients required central arterial and femoral venous access. Extracorporeal membrane oxygenation was initiated in response to hemodynamic collapse due to perforation of left ventricle (n = 2), aortic root rupture (n = 1), moderate-to-severe aortic insufficiency (n = 1), left main impingement (n = 1), valve embolization (n = 1), severe hypotension and cardiac arrest after prolonged rapid pacing sequence (n = 1), ventricular fibrillation (n = 2), and ventricular tachycardia (n = 1). Median time of ECMO support was 87 minutes. There were three hospital deaths. Post-TAVR mean aortic gradient was 8 mm Hg and median hospital stay was 19 days. Additional procedures included valve-in-valve placement (n = 1), percutaneous coronary intervention (n = 1), surgical LV repair (n = 2), surgical valve replacement (n = 1), aortic root rupture repair, and coronary bypass grafting (n = 1). Extracorporeal membrane oxygenation is rescue therapy for hemodynamic instable patients who develop TAVR-related cardiac complications.
经导管主动脉瓣置换术(TAVR)期间或术后的心血管并发症与极高的死亡率相关,但当患者出现呼吸或心脏骤停时,体外膜肺氧合(ECMO)可作为一种手术抢救手段来改善预后。2012年至2014年,230例患者接受了TAVR,10例患者(4.3%)需要紧急静脉-动脉ECMO支持。平均年龄为83岁,胸外科医师协会(STS)评分中位数为15,平均主动脉瓣压差为45 mmHg。左心室射血分数中位数为35%。大多数ECMO的通路为股部;2例患者需要中心动脉和股静脉通路。启动体外膜肺氧合是为了应对因左心室穿孔(n = 2)、主动脉根部破裂(n = 1)、中重度主动脉瓣关闭不全(n = 1)、左主干受压(n = 1)、瓣膜栓塞(n = 1)、长时间快速起搏序列后严重低血压和心脏骤停(n = 1)、心室颤动(n = 2)以及室性心动过速(n = 1)导致的血流动力学崩溃。ECMO支持的中位时间为87分钟。有3例患者在医院死亡。TAVR术后平均主动脉瓣压差为8 mmHg,中位住院时间为